Investigational drugs for anxiety in patients with schizophrenia (Q38271298)

1 September 2017

1 reference

title

Investigational drugs for anxiety in patients with schizophrenia (English)

1 reference

1 September 2017

0 references

4

Pierre-Michel Llorca

1 reference

1 September 2017

2

Ludovic Samalin

1 reference

1 September 2017

Ricardo P Garay

1

1 reference

PubMed ID

25423603

1 September 2017

Ahcène Hameg

series ordinal

3

1 reference

PubMed ID

25423603

1 September 2017

language of work or name

English

0 references

publication date

25 November 2014

1 reference

Expert Opinion on Investigational Drugs

1 September 2017

1 reference

1 September 2017

24

1 reference

1 September 2017

4

1 reference

1 September 2017

507-517

1 reference

Definition and description of schizophrenia in the DSM-5

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Physical illness and schizophrenia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Humanistic burden in schizophrenia: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Anxiety comorbidity in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Anxiety as a core aspect of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

“Meta-guidelines” for the management of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Clinical potential of lurasidone in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pregabalin for the treatment of generalized anxiety disorder: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pregabalin for the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Targeting of NMDA receptors in new treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Glutamate and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Pregabalin in the treatment of schizophrenic anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Augmentation with pregabalin in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Oxytocin in the prelimbic medial prefrontal cortex reduces anxiety-like behavior in female and male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Famotidine in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder pa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

Signaling pathways in schizophrenia: emerging targets and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.987339

10.1517/13543784.2014.987339

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25423603